Re: Farmas USA
buenas tardes! subo un micro estudio de una microcap, creo que podría ser interesante aunque la sigo de hace 2 días y le falte, si es chicharro non grato me decís, culaquier opinión bien recibida!
NTEC
Sintomas parkinson con CBD+THC (cannabis)
Pipeline:
Aug-04-15 09:25AM
Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering $6 per share 6 mill acciones
Apr-04-16 07:00AM
Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's
Nov-28-16 07:30AM
Intec Pharma Enters Agreement with the
Michael J. Fox Foundation Around Its Phase III Trial Recruitment
Mar-10-17 08:54AM
Intec Pharma Announces $10 Million Private Placement $4.3 per share 2,5 mill acciones
Aug-03-17 07:00AM
Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies
Aug-21-17 04:15PM
Intec Pharma Closing of $57.5 Million Public Offering of Ord Shares $4.7 per share 12.2 mil acciones
Apr-10-
18 04:01PM
Intec Pharma (Nasdaq: NTEC) to Ring The Nasdaq Stock Market Closing Bell
(toca la campana para anunciar offering el día siguiente?)
Apr-13-
18 04:01PM
Intec Pharma Closing of $35.4 Million Public Offering of Ordinary Shares $5.25 per share 6,75 milli acciones
Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes.
En febrero 2018 declaran, algunos nombres interesantes:
2018-02-14
EDMOND DE ROTHSCHILD HOLDING S.A. 63,716 shares
2018-02-12
SC 13G
venBio Select Advisor LLC 2,195,705 shares
Último informe breve e interesante:
Mar-09-18 07:00AM
Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
He entendido que as of 31 dec 2017 Tenian 50 mill, gastan unos 10 mill por trimestre ahora con la fase IIII con 300 patients, con el offering abril calculo tendrán unos 70 millones $
Competencia:
Sativex® GWPH
GW Pharmaceuticals plc
Sinemet MRK
Merck & Co., Inc.